Form 8-K - Current report:
SEC Accession No. 0001493152-24-035939
Filing Date
2024-09-12
Accepted
2024-09-12 06:12:24
Documents
42
Period of Report
2024-09-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43503
2 ex99-1.htm EX-99.1 35545
3 ex99-1_001.jpg GRAPHIC 107892
4 ex99-1_002.jpg GRAPHIC 711623
5 ex99-1_003.jpg GRAPHIC 90701
6 ex99-1_004.jpg GRAPHIC 152311
7 ex99-1_005.jpg GRAPHIC 127197
8 ex99-1_006.jpg GRAPHIC 89375
9 ex99-1_007.jpg GRAPHIC 127429
10 ex99-1_008.jpg GRAPHIC 96717
11 ex99-1_009.jpg GRAPHIC 93065
12 ex99-1_010.jpg GRAPHIC 99871
13 ex99-1_011.jpg GRAPHIC 131578
14 ex99-1_012.jpg GRAPHIC 105553
15 ex99-1_013.jpg GRAPHIC 116210
16 ex99-1_014.jpg GRAPHIC 128511
17 ex99-1_015.jpg GRAPHIC 142558
18 ex99-1_016.jpg GRAPHIC 124382
19 ex99-1_017.jpg GRAPHIC 113165
20 ex99-1_018.jpg GRAPHIC 108041
21 ex99-1_019.jpg GRAPHIC 113805
22 ex99-1_020.jpg GRAPHIC 111171
23 ex99-1_021.jpg GRAPHIC 122388
24 ex99-1_022.jpg GRAPHIC 102982
25 ex99-1_023.jpg GRAPHIC 141526
26 ex99-1_024.jpg GRAPHIC 144414
27 ex99-1_025.jpg GRAPHIC 126682
28 ex99-1_026.jpg GRAPHIC 101892
29 ex99-1_027.jpg GRAPHIC 80329
  Complete submission text file 0001493152-24-035939.txt   5420709

Data Files

Seq Description Document Type Size
30 XBRL SCHEMA FILE cldi-20240911.xsd EX-101.SCH 3813
31 XBRL DEFINITION FILE cldi-20240911_def.xml EX-101.DEF 30090
32 XBRL LABEL FILE cldi-20240911_lab.xml EX-101.LAB 36817
33 XBRL PRESENTATION FILE cldi-20240911_pre.xml EX-101.PRE 27113
44 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6006
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 241293827
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)